PhRMA Reconsiders Medicare Stance For 2000: Incremental Reform Weighed
Executive Summary
The linchpin legislative policy decision facing PhRMA for 2000 is whether to endorse an incremental drug benefit that stops short of comprehensive Medicare reform.
You may also be interested in...
PhRMA Moves To Head Off Clinton Assault; Considers Incremental Rx Benefit
The Pharmaceutical Research & Manufacturers of America is attempting to defuse some of the Clinton Administration's rhetoric on drug costs to the elderly ahead of the State of the Union address.
PhRMA Moves To Head Off Clinton Assault; Considers Incremental Rx Benefit
The Pharmaceutical Research & Manufacturers of America is attempting to defuse some of the Clinton Administration's rhetoric on drug costs to the elderly ahead of the State of the Union address.
Canadian Price Controls May Become Higher Priority For PhRMA
The impact of international pharmaceutical price controls on the U.S. Medicare debate may be leading PhRMA to step up its international lobbying efforts, particularly in Canada.